Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib.
Bye AP, Kriek N, Sage T, Rawlings SJ, Prodger C, Kesavan M, Lees C, Booth S, Cowen LG, Shefferd K, Desborough MJ, Gibbins JM, Eyre TA.
Bye AP, et al. Among authors: eyre ta.
Haematologica. 2023 May 1;108(5):1429-1435. doi: 10.3324/haematol.2022.281402.
Haematologica. 2023.
PMID: 36519322
Free PMC article.
No abstract available.